MENU
Showcases Stock ranks Forex

Aveo Pharmaceuticals (AVEO)
15  0 (0%) 01-19 16:00
Open: 14.995 Pre. Close: 15
High: 15 Low: 14.99
Volume: 245,298 Market Cap: 0(M)
Stock Technical Analysis
Overall:     
Target: Six months: 17.52
One year: 20.46
Support: Support1: 14.93
Support2: 14.89
Resistance: Resistance1: 15.00
Resistance2: 17.52
Pivot: 14.96
Moving Averages: MA(5): 14.99
MA(20): 14.96
MA(100): 12.62
MA(250): 8.25
MACD: MACD(12,26): 0.07
Signal(12,26,9): 0.08
%K %D: %K(14,3): 100.00
%D(3): 95.83
RSI: RSI(14): 73.10
52-Week: High: 15
Low: 3.07
Change(%): 354.5
Average Vol(K): 3-Month: 647
10-Days: 491
Prices Prediction (Update @5:00pm)
If tomorrow: Open lower Open higher
High: 15.014 - 15.087 15.087 - 15.15
Low: 14.822 - 14.908 14.908 - 14.982
Close: 14.873 - 15.004 15.004 - 15.118
Price, MAs and Bollinger Bands
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.

[ AVEO ] has closed below upper band by 10.9%. Bollinger Bands are 94.3% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 50 bars. This is a sign that the market may be about to initiate a new trend.
Company profile
AVEO Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing and commercializing medicines for cancer patients. It markets its lead candidate, FOTIVDA, an oral, once-daily, vascular endothelial growth factor receptor tyrosine kinase inhibitor, which is used for the treatment of renal cell carcinoma (RCC); and tivozanib for the treatment of RCC, HCC, immunologically cold tumors, and CCA. The company has also completed a Phase II clinical trial of tivozanib in combination with Opdivo (nivolumab) for the treatment of RCC. In addition, it is developing Ficlatuzumab, a potent humanized immunoglobulin G1 (IgG1) monoclonal antibody that targets hepatocyte growth factor that is in a Phase II clinical trial for the treatment of squamous cell carcinoma of the head and neck, pancreatic cancer, and acute myeloid leukemia; AV-203, a potent humanized IgG1 monoclonal antibody, which completed Phase I clinical trial for treating human ErbB3; and AV-380, a potent humanized IgG1 inhibitory monoclonal antibody that is in a Phase I clinical trial for the treatment or prevention of cachexia. The company's preclinical stage product includes AV-353 that targets the Notch 3 pathway. AVEO Pharmaceuticals, Inc. has collaboration agreements with CANbridge Life Sciences Ltd.; EUSA Pharma (UK) Limited; Novartis International Pharmaceutical Ltd.; Biodesix, Inc.; St. Vincent's Hospital Sydney Limited; Biogen Idec International GmbH; Kyowa Kirin Co., Ltd.; and AstraZeneca PLC. The company was formerly known as GenPath Pharmaceuticals, Inc. and changed its name to AVEO Pharmaceuticals, Inc. in March 2005. AVEO Pharmaceuticals, Inc. was incorporated in 2001 and is headquartered in Boston, Massachusetts.
Stock chart
Stock News
Thu, 28 Mar 2024
CORRECTION – AVEO Oncology Announces Appointment of Chief Medical Officer and Formation of ... - The Bakersfield Californian

Thu, 28 Mar 2024
CORRECTION – AVEO Oncology Announces Appointment of Chief Medical Officer and Formation of Scientific Advisory ... - GlobeNewswire

Tue, 26 Mar 2024
AVEO Oncology to Present at the 31st Annual J.P. Morgan Healthcare Conference - Yahoo Movies Canada

Sun, 24 Mar 2024
AVEO Pharmaceuticals (AVEO) Reports Q2 Loss, Lags Revenue Estimates - Yahoo Movies UK

Thu, 18 Jan 2024
LG Chem's Aveo Oncology Initiates U.S. Phase III Trial for Ficlatuzumab in Head and Neck Cancer - Korea IT Times

Wed, 17 Jan 2024
LG Chem's subsidiary starts phase 3 study of head and neck cancer drug in US - KBR

Financial Analysis
Price to Book Value: Outperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Underperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Neutral
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Underperform
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Outperform
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Stock Basics & Statistics
Exchange:  NASDAQ Capital Market
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. (M) 34.76
Shares Float (M) 34.34
% Held by Insiders 0.19
% Held by Institutions 34.47
Shares Short (K) 817
Shares Short Prior Month (K) 969
Stock Financials
EPS -1.200
Book Value (p.s.) 0.830
Profit Margin -30.79
Operating Margin -25.97
Return on Assets (ttm) -14.6
Return on Equity (ttm) -72.5
Qtrly Rev. Growth 100.7
Gross Profit (p.s.) 0.324
Sales Per Share 2.713
EBITDA (p.s.) -0.703
Qtrly Earnings Growth
Operating Cash Flow (M) -22.66
Levered Free Cash Flow (M) -13.00
Stock Valuation
PE Ratio -12.50
PEG Ratio
Price to Book value 18.07
Price to Sales 5.53
Price to Cash Flow -23.01
Stock Dividends
Dividend
Dividend Yield
Dividend Growth

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android